Characterizing the effects of common UDP glucuronosyltransferase (UGT) 1A6 and UGT1A1 polymorphisms on cis- and trans-resveratrol glucuronidation

Drug Metabolism and Disposition

Volumn 37, Issue 8, 2009, Pages 1726-1732

  Iwuchukwu, Otito Frances ^a   Ajetunmobi, Jumoke ^a   Ung, Din ^a   Nagar, Swati ^a  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCURONIDE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A6; RESVERATROL;

ARTICLE; CELL STRAIN HEK293; CIS TRANS ISOMERISM; CONTROLLED STUDY; DRUG GLUCURONIDATION; ENZYME INHIBITION; ENZYME SUBSTRATE; GENE FREQUENCY; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; TATA BOX;

CELL LINE; GENE FREQUENCY; GENOTYPE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; KINETICS; MICROSOMES, LIVER; PHENOTYPE; POLYMORPHISM, GENETIC; STILBENES; TATA BOX; TISSUE BANKS; TRANSFECTION;

EID: 67650799189     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.027391     Document Type: Article

References (38)

1. Argikar UA, Iwuchukwu OF, and Nagar S (2008) Update on tools for evaluation of uridine diphosphoglucuronosyltransferase polymorphisms. Expert Opin Drug Metab Toxicol 4:879-894.
2. Aumont V, Krisa S, Battaglia E, Netter P, Richard T, Mérillon JM, Magdalou J, and Sabolovic N (2001) Regioselective and stereospecific glucuronidation of trans- and cis-resveratrol in human. Arch Biochem Biophys 393:281-289.
3. Bigler J, Whitton J, Lampe JW, Fosdick L, Bostick RM, and Potter JD (2001) CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. Cancer Res 61:3566-3569.
4. Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, Booth TD, Crowell JA, Perloff M, Gescher AJ, et al. (2007) Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 16:1246-1252.
5. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, Lindhout D, Tytgat GN, Jansen PL, and Oude Elferink RP (1995) The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 333:1171-1175.
6. Butler LM, Duguay Y, Millikan RC, Sinha R, Gagné JF, Sandler RS, and Guillemette C (2005) Joint effects between UDP-glucuronosyltransferase 1A7 genotype and dietary carcinogen exposure on risk of colon cancer. Cancer Epidemiol Biomarkers Prev 14:1626-1632.
7. 2+ handling in A7r5 vascular myocytes. Eur J Pharmacol 577:91-99.
8. Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P, Rogatko A, Wang H, and Blanchard RL (2005) UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/ irinotecan. Clin Cancer Res 11:1226-1236.
9. Chan AT, Tranah GJ, Giovannucci EL, Hunter DJ, and Fuchs CS (2005) Genetic variants in the UGT1A6 enzyme, aspirin use, and the risk of colorectal adenoma. J Natl Cancer Inst 97:457-460.
10. Chen Y, Kuehl GE, Bigler J, Rimorin CF, Schwarz Y, Shen DD, and Lampe JW (2007) UGT1A6 polymorphism and salicylic acid glucuronidation following aspirin. Pharmacogenet Genomics 17:571-579.
11. Ciotti M, Marrone A, Potter C, and Owens IS (1997) Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications. Pharmacogenetics 7:485-495.
12. Fang JL and Lazarus P (2004) Correlation between the UDP- glucuronosyltransferase (UGT1A1) TATAA box polymorphism and carcinogen detoxification phenotype: significantly decreased glucuronidating activity against benzo(a)pyrene-7,8-dihydrodiol(-) in liver microsomes from subjects with the UGT1A1*28 variant. Cancer Epidemiol Biomarkers Prev 13:102-109.
13. Franklin MR and Estabrook RW (1971) On the inhibitory action of mersalyl on microsomal drug oxidation: a rigid organization of the electron transport chain. Arch Biochem Biophys 143:318-329.
14. Gescher AJ and Steward WP (2003) Relationship between mechanisms, bioavailability, and preclinical chemopreventive efficacy of resveratrol: a conundrum. Cancer Epidemiol Biomarkers Prev 12:953-957.
15. Girard H, Thibaudeau J, Court MH, Fortier LC, Villeneuve L, Caron P, Hao Q, von Moltke LL, Greenblatt DJ, and Guillemette C (2005) UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver. Hepatology 42:448-457.
16. Goldberg DM, Yan J, and Soleas GJ (2003) Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 36:79-87.
17. Guillemette C (2003) Pharmacogenomics of human UDP- glucuronosyltransferase enzymes. Pharmacogenomics J 3:136-158.
18. Hutzler JM and Tracy TS (2002) Atypical kinetic profiles in drug metabolism reactions. Drug Metab Dispos 30:355-362.
19. Iwuchukwu OF and Nagar S (2008) Resveratrol (trans-resveratrol, 3,5,4′-trihydroxy-transstilbene) glucuronidation exhibits atypical enzyme kinetics in various protein sources. Drug Metab Dispos 36:322-330.
20. Iyer L, Das S, Janisch L, Wen M, Ramírez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, and Ratain MJ (2002) UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2:43-47.
21. Iyer L, Hall D, Das S, Mortell MA, Ramírez J, Kim S, Di Rienzo A, and Ratain MJ (1999) Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism[ast]. Clin Pharmacol Ther 65:576-582.
22. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, et al. (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275:218-220.
23. Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE, Gonzalez FJ, and Tracy TS (1998) Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37:4137-4147.
24. Krishnaswamy S, Hao Q, Al-Rohaimi A, Hesse LM, von Moltke LL, Greenblatt DJ, and Court MH (2005) UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J Pharmacol Exp Ther 313:1340-1346.
25. Leiro J, Alvarez E, Arranz JA, Laguna R, Uriarte E, and Orallo F (2004) Effects of cis-resveratrol on inflammatory murine macrophages: antioxidant activity and down-regulation of inflammatory genes. J Leukoc Biol 75:1156-1165.
26. Maier-Salamon A, Hagenauer B, Wirth M, Gabor F, Szekeres T, and Jäger W (2006) Increased transport of resveratrol across monolayers of the human intestinal Caco-2 cells is mediated by inhibition and saturation of metabolites. Pharm Res 23:2107-2115.
27. Nagar S, Remmel RP, Hebbel RP, and Zimmerman CL (2004a) Metabolism of opioids is altered in liver microsomes of sickle cell transgenic mice. Drug Metab Dispos 32:98-104.
28. Nagar S, Zalatoris JJ, and Blanchard RL (2004b) Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells. Pharmacogenetics 14:487-499.
29. Orallo F (2006) Comparative studies of the antioxidant effects of cis- and trans-resveratrol. Curr Med Chem 13:87-98.
30. Peters WH, te Morsche RH, and Roelofs HM (2003) Combined polymorphisms in UDP-glucuronosyltransferases 1A1 and 1A6: implications for patients with Gilbert's syndrome. J Hepatol 38:3-8.
31. Raijmakers MT, Jansen PL, Steegers EA, and Peters WH (2000) Association of human liver bilirubin UDP-glucuronyltransferase activity with a polymorphism in the promoter region of the UGT1A1 gene. J Hepatol 33:348-351.
32. Sabolovic N, Humbert AC, Radominska-Pandya A, and Magdalou J (2006) Resveratrol is efficiently glucuronidated by UDP-glucuronosyltransferases in the human gastrointestinal tract and in Caco-2 cells. Biopharm Drug Dispos 27:181-189.
33. Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581-616.
34. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, and Walle UK (2004) High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32:1377-1382.
35. Walle T, Otake Y, Brubaker JA, Walle UK, and Halushka PV (2001) Disposition and metabolism of the flavonoid chrysin in normal volunteers. Br J Clin Pharmacol 51:143-146.
36. Wenzel E, Soldo T, Erbersdobler H, and Somoza V (2005) Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol Nutr Food Res 49:482-494.
37. Yoder Graber AL, Ramírez J, Innocenti F, and Ratain MJ (2007) UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers. Pharmacogenet Genomics 17:619-627.
38. Zhang H, Varlamova O, Vargas FM, Falany CN, Leyh TS, and Varmalova O (1998) Sulfuryl transfer: the catalytic mechanism of human estrogen sulfotransferase. J Biol Chem 273:10888-10892.